Status: Not yet recruiting
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CAR T cell-therapies after lymphodepleting chemotherapy in patients with B cell malignancies with exhausted standard treatment options.
Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, Basel, SwitzerlandUpdated: Dec 24, 2025Locations: 1
Eligibility criteria
Age ≥ 18 years [+16]
Requirement for systemic corticosteroids, i.e. ≥20 mg of prednisone or equivalen... [+13]